Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment

by Olaf Oberschmidt, Stephan Kloess, Ulrike Koehl
Published 2017-06-01

Harnessing NK Cell Checkpoint-Modulating Immunotherapies

by Sachin Kumar Singh Chauhan, Ulrike Koehl, Stephan Kloess
Published 2020-07-01

Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset

by Stephan Kloess, Alessa Ede Valverde da Silva, Olaf Oberschmidt, Tanja Gardlowski, Nadine Matthies, Maulik Vyas, Lubomir Arseniev, Michael Heuser, Elke Pogge von Strandmann, Ulrike Köhl
Published 2017-09-01

Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset

by Stephan Kloess, Alessa Ede Valverde da Silva, Olaf Oberschmidt, Tanja Gardlowski, Nadine Matthies, Maulik Vyas, Lubomir Arseniev, Michael Heuser, Elke Pogge von Strandmann, Ulrike Köhl
Published 2018-10-01

Comparative analysis of clinical-scale IFN-gamma positive T-cell enrichment using partially and fully integrated platforms

by Christoph Priesner, Ruth Esser, Sabine Tischer, Michael Marburger, Krasimira Aleksandrova, Britta Maecker-Kolhoff, Hans-Gert Heuft, Lilia Goudeva, Rainer Blasczyk, Lubomir Arseniev, Ulrike Koehl, Britta Eiz-Vesper, Stephan Kloess
Published 2016-09-01

IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study.

by Claudia Brehm, Sabine Huenecke, Andrea Quaiser, Ruth Esser, Melanie Bremm, Stephan Kloess, Jan Soerensen, Hermann Kreyenberg, Christian Seidl, Petra S A Becker, Heiko Mühl, Thomas Klingebiel, Peter Bader, Jakob R Passweg, Dirk Schwabe, Ulrike Koehl
Published 2011-01-01